GO
Loading...

Pharmaceuticals

More

  • Arkansas court won't reconsider Risperdal case Thursday, 24 Apr 2014 | 11:15 AM ET

    LITTLE ROCK, Ark.— The Arkansas Supreme Court declined on Thursday to reconsider its decision that threw out a $1.2 billion judgment against a pharmaceutical company accused of improperly marketing an antipsychotic drug. In a one-sentence order, the court rejected Arkansas Attorney General Dustin McDaniel's request for a rehearing on the case.

  • April 24- U.S. drugmaker Eli Lilly and Co reported lower-than-expected quarterly revenue on Thursday, hurt by disappointing sales of its cancer and diabetes drugs, and trimmed its 2014 profit forecast. Revenue fell 16 percent to $4.68 billion while Wall Street expected $4.8 billion.

  • AstraZeneca reports profits fall as predators circle Thursday, 24 Apr 2014 | 5:34 AM ET
    Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc.

    The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."

  • ZURICH, April 24- Swiss drugmaker Novartis posted a weaker-than-expected 1 percent rise in quarterly sales, underscoring the pressures from generic competition and tighter healthcare budgets that led it to announce a radical business overhaul earlier this week.

  • Novartis profit boosted by transfusion test unit sale Thursday, 24 Apr 2014 | 3:03 AM ET

    Novartis posted first-quarter profit that beat expectations, boosted by an exceptional gain from the sale of its blood transfusion test unit.

  • After court drama, Oklahoma to have 2 executions Thursday, 24 Apr 2014 | 2:34 AM ET

    OKLAHOMA CITY— The Oklahoma Supreme Court has ruled that two death row inmates are not entitled to know the source of the drugs that will be used to kill them, putting them both on track to be executed as early as next week.

  • James West, healthcare analyst at Results Healthcare, says the pharmaceutical sector is "dynamic" and the flurry of deals is likely to continue.

  • COLUMN-When the best offense is defensive stocks Wednesday, 23 Apr 2014 | 4:30 PM ET

    LONG BEACH, Calif., April 23- You've been on offense with your global stock portfolio for five years, running up the score in sectors like consumer discretionary and technology stocks that have outperformed the broad market. Jamie Doyle, co-manager of the Causeway Global Value Fund, is not ready to make a wholesale switch into defensive plays.

  • LONDON, April 23- The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pharmaceuticals sector and beyond.

  • How Ackman built Allergan stake     Wednesday, 23 Apr 2014 | 12:41 PM ET

    CNBC's Eamon Javers reports on Bill Ackman's stake in Allergan. Javers says this is a classic case of insider trading that is not against the rules.

  • William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • Ackman: Allergan clear fit for Valeant     Wednesday, 23 Apr 2014 | 7:41 AM ET

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • US STOCKS-Futures flat after six straight days of gains Wednesday, 23 Apr 2014 | 7:41 AM ET

    *Gilead Sciences rises in premarket after results. *Key earnings on tap; Apple, Facebook out after the close. *Gilead Sciences Inc rose 3.8 percent to $75.60 in heavy premarket trading a day after the drugmaker reported a sharp increase in its quarterly profit, helped by sales of its hepatitis C drug.

  • J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets     Wednesday, 23 Apr 2014 | 7:33 AM ET

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold     Wednesday, 23 Apr 2014 | 7:32 AM ET

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Investor pressure pushing drugmaker M&A deals Wednesday, 23 Apr 2014 | 6:11 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.

  • Asia shares mixed on lackluster China data Wednesday, 23 Apr 2014 | 12:06 AM ET

    TOKYO— Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector. Overnight, U.S. financial data and corporate earnings helped spur gains from deals by Switzerland's Novartis with Britain's GlaxoSmithKline PLC and the Eli Lilly& Co. of the U.S.

  • Investor pressure pushing drugmaker M&A deals Tuesday, 22 Apr 2014 | 6:41 PM ET

    Swiss drugmaker Novartis AG on Tuesday said it's trading its vaccine business for GlaxoSmithKline Plc's cancer drug business and selling its veterinary drug business to Eli Lilly and Co. Meanwhile, Canadian drugmaker Valeant Pharmaceuticals International Inc. said it teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $45 billion.

  • April 22- At any given time, the acquisitive chief executive of Valeant Pharmaceuticals Inc is brokering multiple deal discussions and eyeing as many as 50 buying opportunities. Pearson's latest target, with help from activist investor Bill Ackman, is Allergan Inc, maker of anti-wrinkle treatment Botox.

Most Popular Video

Thursday, 24 Apr 2014 | 2:30 PM ET

Sell in May? It's an old cliché but the problem is it's sometimes right! But earnings keep rolling in better than expected. CNBC's Patti Domm explains.

Thursday, 24 Apr 2014 | 1:16 PM ET

Discussing whether boards of directors are necessary for companies, and the importance of them pushing back, with Stuart Grant of Grant & Eisenhofer, and Brad Feld, author of "Startup Boards."

Thursday, 24 Apr 2014 | 1:33 PM ET

CNBC's Diana Olick reports DR Horton announced a new bargain brand targeted at the entry-level buyer.